CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Part...
Phase 3
Budapest, Hungary and 561 other locations
Primary Objectives:To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemi...
Phase 3
Budapest, Hungary and 20 other locations
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medici...
Phase 3
Budapest, Hungary and 103 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Budapest, Hungary and 751 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Budapest, Hungary and 178 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Budapest, Hungary and 762 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Budapest, Hungary and 165 other locations
in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to \< 18 years of age, with chronic kidney di...
Phase 3
Budapest, Hungary and 22 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Budapest, Hungary and 1072 other locations
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN.This s...
Phase 3
Budapest, Hungary and 565 other locations
Clinical trials
Research sites
Resources
Legal